Prostate cancer (PCa) is the most common visceral malignancy and the second leading cause of cancer deaths in US men. There is broad evidence that FGF receptors are important in PCa initiation and progression, but the contribution of particular FGFs in this disease is not fully understood. The FGF family members FGF19, FGF21 and FGF23 comprise a distinct subfamily that circulate in serum and act in an endocrine manner. These endocrine FGFs require Į-Klotho 
INTRODUCTION
Prostate cancer (PCa) is the most common malignancy in American men, affecting one in nine men over 65 years of age. Currently there is no effective cure for advanced stages of PCa and it is the second-leading cause of male cancer mortality. Identification of novel endogenous factors responsible for proliferation, migration and invasion of PCa will facilitate the understanding of the biology of PCa progression and the development of new approaches for the diagnosis and treatment of this disease.
The human fibroblast growth factor (FGF) family is composed of 22 structurally related polypeptides. The FGF genes can be divided into three major groups (see (1) for review).
FGF1-10, 16-18, 20 and 22 are classical FGFs. They are mitogens that bind strongly to heparin, which is abundant in the extracellular microenvironment, so these FGFs tend to act locally.
FGFs 11-14 are not secreted mitogens and they appear to modulate electrical excitability and as such do not appear to play a role in cancer. A major new discovery in the last decade is the characterization of the endocrine FGFs (FGF15/19, FGF21, and FGF23). FGF15 is the mouse homolog of human FGF19 and has analogous functions in mice. This subfamily is secreted into serum and they are stable in this environment which allows them to act in an endocrine fashion (2) . Another common feature shared by this atypical FGF family is their requirement for Į-Klotho (KL) and/or ȕ-Klotho (KLB), two related single-pass transmembrane proteins with restricted tissue distribution for potent biological activity (3) . Both KL and KLB act as co-receptors with the classic FGF receptors (FGFRs) in relevant target tissues to facilitate the FGF-FGFR interaction for endocrine FGFs. The tissue specific actions of the endocrine FGFs are thus modulated by
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The only endocrine FGF that has been examined in cancer is FGF19. Prior to the identification of the KL /KLB binding partners for this subfamily, it was reported that FGF19 displays binding specificity for FGFR4 at relatively high concentrations (2, 8) ; however, studies in HEK293 and L6 cells show that in the presence of KLB, FGF19 binds and signals through multiple FGFRs (9) , with FGFR1 and FGFR4 being more potent than FGFR2 or FGFR3. KL can also act as a co-receptor for FGF19 (10) (11) although the exact FGFR specificity has not been determined. Although FGF19 was first reported to be expressed in a colon adenocarcinoma cell line a decade ago (8) , its relevance to cancer had not been evident until it was discovered that the transgenic mice overexpressing FGF19 in skeletal muscle develop hepatocellular carcinoma (12) , which presumably reflects an endocrine action of the increased levels of circulating FGF19. FGF19 has been found to be co-expressed in a subgroup of primary human liver, colonic and lung squamous carcinomas and in a subset of human colon cancer cell lines (13) .
An anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4 inhibits growth of colon tumor xenografts in vivo and effectively prevents hepatocellular carcinomas in FGF19 transgenic mice. The efficacy of the antibody in these models is linked to the inhibition of FGF19-dependent activation of FGFR4 and downstream targets FRS2, ERK and ȕ-catenin (14) . The inactivation of FGF19 could be beneficial for the treatment of malignancies involving the interaction of FGF19 and FGFRs.
All FGF ligands, including endocrine FGFs, signal through four highly conserved transmembrane tyrosine kinase receptors (FGFR1-4) with differential affinity for various FGF ligands. FGFR signaling has been strongly implicated in prostate tumorigenesis (15) . Our laboratory has shown that FGFR1 is expressed in clinically localized PCas based on immunohistochemistry (IHC) and Western blotting of PCa extracts (16) . Studies in transgenic mice have shown that chronic FGFR1 activation can lead to adenocarcinoma and epithelialmesenchymal transition of the cancer cells (17) . We (18) and others (19) (20) (21) have shown that there is increased expression of FGFR4 in PCa by immunohistochemistry (IHC) and this has been confirmed by quantitative RT-PCR (Q-RT-PCR). Strong FGFR4 expression is significantly associated with poor clinical outcome (19, 21) . For example, recent work by Murphy et al (21) has shown that increased FGFR4 expression is strongly associated with PCa specific death as was decreased expression of the FGFR signaling inhibitor Sef. Thus both correlative studies in human tissues and mouse models strongly support the concept that FGFR1 and FGFR4 both play an important role in PCa.
Our group has previously shown that FGF19 is expressed as a paracrine factor in PCa reactive stroma based on analysis of laser captured normal and PCa stroma (22) . However, to date, the role of FGF19 in PCa has not been comprehensively addressed. Our data indicates that FGF19 is expressed in PCa and that FGF19 signaling plays an important role in prostate cancer tumorigenesis and progression. 
MATERIALS and METHODS

Cell
Prostate and prostate cancer tissues. Tissue samples were obtained from Baylor Prostate
Cancer Program Tissue Bank and were collected from fresh radical prostatectomy specimens after obtaining informed consent under an Institutional Review Board approved protocol. Laser capture of epithelial and stromal RNAs from frozen tissues was carried out as described previously (22) . Paraffin-embedded tissues from these specimens were used to construct small tissue microarrays for immunohistochemistry. Western Blot. Total cellular protein lysate was prepared as described previously (23) . Briefly, cells were lysed in modified RIPA buffer containing Tris 50 mM, NaCl 150 mM, Triton X-100 1%, SDS 0.1%, deoxycholate 0.5%, sodium orthovanadate 2 mM, sodium pyrophosphate 1mM, NaF 50mM, EDTA 5 mM, PMSF 1 mM and 1x protease inhibitor cocktail (Roche) and clarified by centrifugation. Protein concentration of the lysates were determined using BCA protein assay kit (Thermo Scientific, Waltham, MA, USA). 40μg of the extracted protein from each sample was subjected to electrophoresis in 10% to 15% SDS PAGE, dependent on the molecular weight of the proteins to be analyzed. Proteins in the gels were transferred onto Immobilon-P polyvinylidene difluoride membranes (Invitrogen) and subjected to Western blotting with different antibodies. The antibodies (Ab) were from Cell Signaling Technology Inc (Danvers, MA, USA) and included: phospho-FRS2 (Tyr196) rabbit polyclonal antibody; phospho-p44/42 MAPK (p-Erk1/2) rabbit mAb; p44/42 MAPK (Erk1/2), phospho-p38 MAPK (Thr180/Tyr182) rabbit mAb, phospho-MEK1/2 (Ser217/221) rabbit mAb , MEK1/2 rabbit mAb, phospho-AKT (Ser473) rabbit mAb, phospho-AKT (Thr308) rabbit mAb, and total AKT rabbit mAb. All were used at a 1:1000 dilution. A goat polyclonal anti-β-actin antibody (Santa Cruz Biotech, Santa Cruz, CA) was utilized at 1:1000 as loading control. After incubation with primary antibodies for overnight at 4ºC or for 1 hour at room temperature, horseradish peroxidase-labeled secondary antibodies were then applied to the membranes for 1 h at room temperature. Signals were visualized using enhanced chemiluminescence Western blotting detection reagents (Thermo).
Immunohistochemistry. FGF19 immunohistochemistry (IHC) was carried out using the general procedures described previously (24) . Antigen retrieval was performed in Tris-EDTA, 
FGF19 Enzyme-linked immunoabsorption assay (ELISA). FGF19 expression in stable
shRNA mediated FGF19 gene knockdown PC3 cells was quantified by ELISA. Cell lysates were prepared as described above for Western blot. Protein concentration were determined using BCA protein assay kit (Thermo) and equal amounts of protein lysates were subjected to ELISA for FGF19 (R&D Systems, Catalog Number: DF1900) as per the manufacturer's instructions.
Gene expression analysis. KL mRNA levels were examined in various public expression datasets, including the "Expo" dataset (GEO accession number GSE2109), of cancers from various histological subtypes, and the Roth et al (25) As seen in Fig 2C, FGF19 significantly enhances PC3 and DU145 cells adhesion on both type I collagen and Matrigel even at concentrations as low as 0.25 ng/ mL and 0.5 ng/ mL.
FGF19 stimulates PCa cell invasion.
To evaluate the effect of FGF19 on PCa cell invasion, we conducted invasion assays using Matrigel invasion chambers. After incubation with or without 25 ng/mL of FGF19 for 24 hours (PC3), 36 hours (DU145), or 72 hours (LNCaP and PNT1a), cell invasion was analyzed as described previously (23) . FGF19 promotes prostate cancer cell invasion by approximately 140 to170% for all cell lines (Fig. 2D) . FGF19mRNA expression in DU145 cells was suppressed by 40-45% and DU145 invasiveness was inhibited by about 25-30% (Fig. 4A ). PC3 FGF19 mRNA was decreased 25-50% and invasion was decreased 45-60% (Fig 4B) . The effects on viable cell number were less striking (<10% decrease), although still statistically significant. Of note, there was an associated decrease in cell viability from approximately 96% to 85-89% for both cell lines using either shRNA (Supplementary Figure 1) . We did not see a statistically significant decrease in Ki67 labeled cells (data not shown). Thus the decrease in viable cell number was in large part due to a small but significant decrease in cell viability.
We then established stable cell lines in PC3 cells using the two shRNAs and analyzed the cell lines for FGF19 protein expression, proliferation and invasion (Fig 4C) . FGF19 protein, as determined by ELISA, was decreased by approximately 50% for both shRNAs cell lines. striking is the impact on invasion and our findings indicate that a significant fraction of cancer invasion in these two cell lines can be attributed to autocrine FGF19 expression.
We then carried out a subcutaneous xenograft experiment with one of the stable shFGF19 PC3 cells lines and vector controls. FGF19 knockdown resulted in a marked inhibition of tumor growth with minimal growth of tumor between days 13 and 32 after inoculation ( Fig   4D) . Figure 5B . The other 9 cases were negative (Fig 5B, lower right) Figure 6A . Examination of the Oncomine data bases reveals that KL is significantly higher in PCa (as well as in renal cell carcinoma) compared to other cancers (t-test p=4 X 10 -45 ; upper Fig 6B) . Of note, KL is also significantly higher in normal prostate (p=2 x10 -9 , lower Fig 6B) and kidney compared other normal tissues.
Analysis of KLB expression using the laser captured samples described above showed no expression in normal epithelium while expression was seen in 4 of 14 normal stromal samples. Two of 7 cancer epithelial samples and 4 of 7 cancer stroma samples expressed KLB.
The data from the epithelial samples is shown in Fig 6A. Of note, one cancer sample expressed both KL and KLB and overall 3 of 7 cancer epithelia express one or both Klotho co-receptors.
Examination of the Oncomine database shows that KLB is significantly upregulated in PCa versus normal prostate in multiple microarray datasets, including the Luo, Varambally, Varanaja and Lapointe datasets (Fig 6C, p<.05 for each dataset).
Immunohistochemical staining with anti-KL antibody showed variable expression of KL in normal and cancer epithelium. As shown in Fig 7A, there is robust expression of KL in the tubules of the kidney, which is a well known site of KL expression by IHC, and negative control showed no staining (not shown). Examination of a small tissue microarray of primary PCa tissues revealed a dichotomous staining pattern. 
DISCUSSION
We have established for the first time that FGF19 plays a role in human prostate cancer. average concentrations are in the range of 0.2-0.4 ng/ml throughout the course of the day. We see statistically significant effects on PCa proliferation and adhesion in vitro at these levels of FGF19. The constant presence of FGF19 over decades may thus promote prostate cancer initiation and/or progression in an endocrine manner in vivo. Thus FGF19 can act as an autocrine, paracrine and endocrine growth factor in PCa. Additional studies will be needed to clarify the relative importance of these modes of action but it is likely to be variable between different tumors depending on the levels of autocrine and/or paracrine FGF19 expression.
In order to respond to low concentrations of FGF19 a Klotho co-receptor must be 
cancers as well as PCa both express significantly higher levels of KL than other cancers, suggesting that expression of KL is not universal in cancers and may reflect differences in the underlying biology of these tumors compared to other cancers. (33) and there are also more modest increases in FGF19 (34) . Patients with less severe renal dysfunction also have elevated FGF23 (35) . Of note, higher serum calcium, which is associated with higher FGF23 (33) is significantly associated with the incidence of fatal PCa (36) (37) .
Similarly, FGF21 has been shown to be increased in obesity (38) , which is linked to fatal PCa (39) . Finally, FGF23 can potentially act as a paracrine factor in bone, the primary metastatic site for PCa, since it is produced predominantly in osteoblasts and osteocytes (40) . 
